AVADEL PHARMACEUTICALS PLC (NASDAQ:AVDL) Files An 8-K Results of Operations and Financial ConditionItem 2.02Results of Operations and Financial Condition.
On August8, 2017, Avadel Pharmaceuticals plc (the “Company”) issued a press release announcing its earnings for the quarter ended June30, 2017. That press release is attached as Exhibit 99.1 and is incorporated herein by reference.
The information responsive to this Item 2.02 of this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 (the “Securities Act”) or the Exchange Act, except as may be expressly set forth by specific reference in such a filing.
Item 9.01Financial Statements and Exhibits.
(d) Exhibits
|
99.1 |
Press release dated August8, 2017, issued by Avadel Pharmaceuticals plc * |
* This information shall be deemed to be "furnished" and not filed herewith.
AVADEL PHARMACEUTICALS PLC ExhibitEX-99.1 2 q22017earningsrelease.htm EXHIBIT 99.1 Exhibit Avadel Pharmaceuticals Reports Second Quarter 2017 ResultsTotal Revenues Increased 19% on a Year-Over-Year Basis to $46.3 MillionStrong Year-to-Date Operating Cash Flow of $33.5 Million Dublin,…To view the full exhibit click here
